Navigation Links
New drug screening identifies chemical agents with potent anti-cancer activity
Date:1/5/2012

Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). These findings could rapidly be implemented into a clinical trial to test how effective the treatment would be.

The discovery of new chemical agents capable of modulating a disease is a long and expensive process. An alternative approach that is just beginning to be explored is the potential repurposing of already established drugs which have been approved for clinical use. The current study examined the newly assembled National Institutes of Health (NIH) Chemical Genomic Center's pharmaceutical collection, which contains 2,816 approved drugs and bioactive compounds and sought to identify agents with an anti-cancer effect in thyroid cancer cell lines.

"To our knowledge, this is the first study to use such a large collection of clinical drugs to test anti-proliferative effect in cancer cells," said Electron Kebebew, MD, of the National Cancer Institute in Bethesda, MD and lead author of the study. "The compounds found to have potent activity in our screen represent possible opportunities to repurpose these drugs for the treatment of patients with aggressive recurrent or metastatic thyroid cancer."

In this study, researchers used a quantitative high-throughput screening (qHTS) approach to examine the effect of 2,816 clinically approved drugs on thyroid cancer cells. qHTS is a titration-based screening paradigm where compounds are screened at multiple concentrations. By employing this approach, researchers found numerous agents across different therapeutic categories and mode of action that had an anti-cancer effect.

"Clinicians can more readily translate these findings into therapy when the drug characteristics are well-known. The drugs can then be used in developing clinical trials or in some cases for off-label use," said Kebebew. "Furthermore, qHTS could be used for identifying therapeutics not only for cancer, but for many other diseases."


'/>"/>
Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Self-affirmation may break down resistance to medical screening
2. Screening Alone Not Enough to Prevent Sudden Death in College Athletes
3. Making Sense of Cancer Screening Updates
4. IASLC sets up committee to move CT lung cancer strategic screening forward
5. American Cancer Society revises cancer screening guideline process
6. Biopsy referral after PSA screening stays consistent over time
7. NCAA mandatory sickle cell screening program not enough to save athletes lives
8. British Screening Program Finding More Early Stage Colon Cancers
9. Mammography screening reduced risk for death from breast cancer by half
10. Targeted Drugs, Lung CT Screening Top Cancer Advances in 2011
11. Studies of patients with cirrhosis uncover limitations in liver cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... throughout Arkansas that offers insurance and financial preparation services, is providing an update ... City Rescue organization. , Rock City Rescue is a locally recognized nonprofit that ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: